Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1") |
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
||
Line 21: | Line 21: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ Frankel et al. 2014 (STU 012013-061)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ Frankel et al. 2014 (STU 012013-061)] | ||
|2013-NR | |2013-NR | ||
− | | style="background-color:#ffffbe" |Phase 1/2, | + | | style="background-color:#ffffbe" |Phase 1/2, fewer than 20 pts |
|- | |- | ||
|[https://doi.org/10.1056/NEJMoa1815105 Pemmaraju et al. 2019 (STML-401-0114)] | |[https://doi.org/10.1056/NEJMoa1815105 Pemmaraju et al. 2019 (STML-401-0114)] |
Revision as of 06:59, 18 July 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Frankel et al. 2014 (STU 012013-061) | 2013-NR | Phase 1/2, fewer than 20 pts |
Pemmaraju et al. 2019 (STML-401-0114) | 2014-2017 | Phase 1/2 (RT) |
Targeted therapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains dosing details in manuscript PubMed NCT02113982
- Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article PubMed